Portfolio companies for the Curevc
Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body. Focus/Therapeutic Area: Oncology Stage/Status: Seed Website: https://www.xenimmune.com
With a novel approach to precision oncology, Tasca Therapeutics is unlocking post-translational modification of proteins by utilizing our state-of-the-art chemical biology and computational approaches, and combining with inhibition at key metabolic nodes to generate drugs for previously considered undruggable targets. Tasca is focused on using its proprietary platform to develop small molecule drugs for hard-to-treat
Tasca Therapeutics Read More »
Advancing off-the-shelf dopamine neuron replacement therapies as a disease-modifying and potentially curative treatment for neurological disorders. Our proprietary platform leverages a novel approach to treating central nervous system disorders, such as Parkinson’s disease, by replacing neurons lost due to neurodegeneration. Focus/Therapeutic Area: Neurodegenerative Stage/Status: Series A Website: https://www.kenaitx.com
Kenai Therapeutics Read More »
Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body. Focus/Therapeutic Area: Text here Stage/Status: Text here Website: https://www.website.com
Stealth Mode Newco – microRNA Therapeutics Company Read More »
Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body. Focus/Therapeutic Area: Text here Stage/Status: Text here Website: https://www.website.com
Stealth Mode Newco – New Therapeutic Leads From Exercise Stimulated Muscle Company Read More »
Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body. Focus/Therapeutic Area: Text here Stage/Status: Text here Website: https://www.website.com
Stealth Mode Newco – Condition-Specific Biologic Therapeutics Company Read More »
Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body. Focus/Therapeutic Area: Text here Stage/Status: Text here Website: https://www.website.com
Stealth Mode Newco – Nonviral Delivery Platform Company Read More »
Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body. Focus/Therapeutic Area: Text here Stage/Status: Text here Website: https://www.website.com
Undisclosed – Revenue Stage Digital Health Company Read More »
